Abstract:Background There is a need for more data examining the outcomes of using donor hearts with moderate/severe left ventricular hypertrophy (LVH). Objectives This study aimed to assess the outcomes of using donor hearts with moderate/severe LVH and evaluate whether outcomes were affected by the 2018 OPTN/UNOS allocation changes. Methods The UNOS database was queried for heart transplants occurring within one year of the October 18, 2018 OPTN/UNOS changes. Pre- and post-2018 changes cohorts were stratified by LVH: non-LVH (left ventricular wall thickness [LVWT] <= 1.1 cm), mild LVH (LVWT 1.2-1.3 cm), or moderate/severe LVH (LVWT ≥ 1.4 cm). The primary outcome was two-year mortality. The secondary outcomes were allograft rejection and cardiac allograft vasculopathy (CAV) at two years. Multivariate regression models were made for both the overall cohort and LVH cohorts. Results 4295 patients were analyzed. Mortality was similar across non-LVH (12%), mild LVH (12%), and moderate/severe LVH (15%) cohorts, p=0.589, including when non-LVH and moderate/severe LVH were directly compared (p=0.340). CAV (p=0.526) and rejection (p=0.675) were also similar across the three groups, including when non-LVH and moderate/severe LVH were directly compared (CAV: p=0.904; rejection: p=0.393). When a subgroup of moderate/severe LVH cohort with concomitant donor hypertension was compared against the non-LVH cohort, mortality p=0.163 and CAV p=0.680 were similar, with rejections significantly lower (7% vs. 23%, p=0.016). Outcomes for moderate/severe LVH remained similar after the 2018 changes: mortality (p=0.868), rejection (p=0.237), CAV (p=0.373). In multivariate regression for the overall cohort, moderate/severe LVH status was not associated with mortality (p=0.512), rejection (p=0.486), or CAV (p=0.563). In multivariate regression for the LVH cohort primary and secondary outcomes were not associated with LVWT (mortality: p=0.519; CAV: p=0.358; rejection: p=0.885) or the 2018 OPTN/UNOS allocation changes (mortality: p=0.372; CAV: p=0.096, rejection: p=0.086). Conclusions Clinical outcomes at two years were similar among recipients of hearts with or without moderate/severe LVH. Outcomes in recipients of donor hearts with moderate/severe LVH remained similar following the 2018 OPTN/UNOS allocation changes.

The impact of the OPTN policy change on patients with a durable left ventricular assist device and chronic kidney disease: Analysis of the UNOS database

Survival After Simultaneous Heart-kidney Transplant in Recipients With a Durable LVAD and Chronic Kidney Disease: Effect of the 2018 Heart Allocation Policy Change

Three-Year Left Ventricular Assist Device Outcomes and Strategy After Heart Transplant Allocation Score Change

Impact of Heart Transplant Allocation Change on Waitlist Mortality and Posttransplant Mortality in Patients With Left Ventricular Assist Devices

Impact of the 2018 change in US allocation policy on adults with congenital heart disease

Regional differences in recipient waitlist time and pre- and post-transplant mortality after the 2006 United Network for Organ Sharing policy changes in the donor heart allocation algorithm

Outcomes Using Donor Hearts With Moderate To Severe Left Ventricular Hypertrophy After The 2018 OPTN/UNOS Allocation Changes

Impact of new allocation policy on waitlist and transplant outcomes of adult congenital heart patients supported with ECMO

Impact of the United Network for organ sharing 2018 donor heart allocation system on transplant morbidity and mortality

Effects of the March 2021 Allocation Policy Change on Key Deceased-donor Kidney Transplant Metrics

The Impact of Local Programmatic Decisions on Outcomes in Transplant-Listed Adults With Congenital Heart Disease

Trends in Mechanical Circulatory Support utilization, Left Ventricular Assist Device implantation and Transplant during Cardiogenic Shock Hospitalizations, after the New Heart Allocation Policy

Impact of kidney transplant on post‐operative morbidity and mortality in patients with pre‐operative cardiac dysfunction

Impact of chronic kidney disease on in-hospital outcomes following left ventricular assist device placement: A national perspective

Impact of OPTN policy 3.7D providing waiting time modification for candidates affected by race‐inclusive eGFR calculations: Early results from a single center

Impact of post-transplant stroke and subsequent functional independence on outcomes following heart transplantation under the 2018 United States heart allocation system

Evolution of Status 1A Heart Transplant Candidates

Revised Heart Allocation Policy Improved Waitlist Mortality and Waiting Time With Maintained Outcomes in En-Bloc Heart-Lung Transplant Candidates and Recipients

Extracorporeal membrane oxygenation bridge to heart transplant: Trends following the allocation change

Early Renal Outcomes Following Heart Transplantation Using Organs Procured After Circulatory Death

Impact of age over 70 years in the new allocation system on the outcomes of heart transplantation in the US